Pulmonary Arterial hypertension (PAH) Market Share, Trend, Segmentation and Forecast to 2026

Pulmonary Arterial hypertension (PAH)

PUNE, MAHARASHTRA, INDIA, February 13, 2018 /EINPresswire.com/ --

WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Opportunity Analyzer: Pulmonary Arterial Hypertension - Opportunity Analysis and Forecasts to 2026”

Pulmonary Arterial hypertension (PAH)


Pulmonary arterial hypertension (PAH) is a rare, fatal cardiopulmonary disease with an annual mortality rate of 15%. The disease is a subset (Group 1) within the World Health Organization’s (WHO’s) classification of the different types of pulmonary hypertension (PH). PAH is characterized by an abnormal rise in the resting mean pulmonary arterial pressure (>25mmHg compared with normal levels of around 14mmHg. ). This increased pressure is caused by pulmonary arterial obstruction due to endothelial dysfunction and vascular remodeling, and leads to increased resistance in the arterial blood vessels

Click here for sample report @ https://www.wiseguyreports.com/sample-request/2775734-opportunityanalyzer-pulmonary-arterial-hypertension-opportunity-analysis-and-forecasts-to-2026

Top Companies mentioned

Actelion Pharmaceuticals (now key subsidiary of Johnson & Johnson)

Arena Pharmaceuticals Bayer

Eiger BioPharmaceuticals

Eli Lilly




Mochida Pharmaceutical

Nippon Shinyaku Co. Ltd


Major Highlight

Since PAH is a progressive disorder, the pulmonary pressure keeps building up as the patient advances through the later stages of the disease, leading to reduced cardiac output, right heart failure, and ultimately, death.

The 5EU market is anticipated to grow the fastest of the three regions, recording a CAGR of 5.4%, while the US and Japan will each record CAGRs of 1.2% and 1.0%, respectively. At the end of 2026, the US will contribute around 67% of global sales, while the 5EU and Japan will account for 28% and 5% of global sales, respectively.

The higher sales numbers for the US can be attributed to the higher price of pharmaceuticals and the greater diagnosed prevalence of PAH in the region.


Overview of pulmonary arterial hypertension, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. 

Annualized PAH therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026. 

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PAH therapeutics market. 

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Analysis of the current and future market competition in the global PAH therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.


For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2775734-opportunityanalyzer-pulmonary-arterial-hypertension-opportunity-analysis-and-forecasts-to-2026

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:


Partner Relations & Marketing Manager



Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.